Fingerprint
Dive into the research topics of 'Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study
Francis J. Giles, Gianantonio Rosti, Photis Beris, Richard E. Clark, Philipp Le Coutre, Francois Xavier Mahon, Juan Luis Steegmann, Peter Valent, Giuseppe Saglio
Research output: Contribution to journal › Review article › peer-review
34
Scopus
citations